G astric cancer treatment is presently characterized by one major issue: After international consensus about the core points in surgical technique, with special respect to the extent of resection and lymphadenectomy, recent prognostic benefit seems to be based on multimodal therapy. Most likely, patients with beginning tumor-cell dissemination beyond the resection margins will benefit from additional therapy. The individualization of therapy and the individual prediction of the patients' risk of relapse will be the task for the future.
New inputs from molecular analysis add to the number of factors that are significantly associated with prognosis. These studies are costly and mostly restricted to centers with high-tech laboratories and long-term results of these methods are not yet available. The majority of institutions treating gastric cancer patients still depend on easy accessible clinical parameters to predict survival. The concept of combining multiple clinically available prognostic factors in a scoring system is of great interest and might serve as an excellent basis for clinical decision making, for the planning of adjuvant therapy, for setting up follow-up schedules, as well as for the evaluation of more sophisticated molecular research.
Kattan et al established a nomogram derived from 1039 patients who underwent R0-gastric cancer resection at Memorial Sloan-Kettering Cancer Center, New York. 1 The nomogram combines easily accessible factors: sex, age, tumor location, Lauren histotype, number of histologic positive and negative nodes, as well as depth of invasion ( Fig. 1) , data that should be available in every institution performing gastriccancer surgery.
Kattan et al were able to predict individual disease-free 5-year survival superior to survival-prediction from the American Joint Committee on Cancer (AJCC) 1997 stage grouping, which is identical to the International Union Against Cancer (UICC) 1997 classification. However, it was unknown if the nomogram's ability for survival-prediction was comparable when used on a different patient-population undergoing surgery in an European center. The centers in question (Department of Surgery, Memorial Sloan-Kettering Cancer Center, New, York, NY; Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany) are comparable in terms of caseload and overall survival and use similar surgical strategies in the treatment of gastric cancer. In both centers, a D2-lymphadenectomy according to the Japanese Research Society for the Study of Gastric Cancer 2 is aimed at for curative gastriccancer surgery.
We now report the validation of the US-derived nomogram on the patient population from our gastric cancer database by comparing nomogram predicted survival with actual survival.
PATIENTS AND METHODS
Between January 1, 1985 and December 31, 2003, 991 patients had undergone R0 resection for gastric cancer at the Klinikum rechts der Isar, Technical University of Munich (MRI). A R0 resection was defined as complete histologic clear margins according to UICC/AJCC standards. The extent of resection was determined by tumor site, tumor stage, and Lauren histotype. 3, 4 A subtotal gastrectomy was performed in patients with pT1/2 carcinomas with an intestinal-type growth pattern, located in the distal third of the stomach. Independent of tumor localization and Lauren histotype, all other patients were treated with a total gastrectomy. The resection was extended to the distal esophagus when required by tumor spread and location, which was the case in nearly all of the tumors located at the gastroesophageal junction (GEJ). The tail of the pancreas and the spleen were only resected when directly involved by the tumor. 4 A D2 lymphadenectomy was performed on a routine basis.
The nomogram by Kattan et al was evaluated on a comparable number of 1039 R0 resections for gastric cancer at Memorial Sloan Kettering Cancer Center (MSKCC) between July 1, 1985 and June 30, 2002 . Depending on the location of the primary lesion, total, distal subtotal, or proximal gastrectomy was performed. Hereby most of the tumors located at the GEJ were treated by a subdiaphragmatic, proximal gastrectomy, while essentially all distal lesions had a high subtotal resection, regardless of T stage. Additional organ resection was performed to facilitate a more extensive lymph node dissection or to gain complete tumor resection. A D2 lymphadenectomy was routinely aimed at. 5 Of the 991 patients from our database, 862 records (87%) were complete regarding the information needed for calculation of nomogram predictions and were therefore included in the present analysis.
Cox proportional hazards regression analysis was used for multivariate analysis. Discrimination of the nomogram was quantified with the concordance index. 6 The concordance index is a modification of the area under the receiver operating characteristic curve (AUC). It was adapted to fit censored data. 6 Its interpretation is similar to AUC.
Calibration was assessed using the quartiles of the predicted survival at 5 and 9 years and calculation of the corresponding observed Kaplan-Meier estimates. Significance was set to 5%. All statistical tests were performed 2-sided.
RESULTS
The 2 patient populations ( Table 1) were comparable regarding male to female ratio, distribution of Lauren histotype, as well as tumor size. Regarding tumor localization a higher percentage of tumors seen at MSKCC was located in the proximal or upper one third (16.5% versus 8.8%), while at MRI a higher percentage of tumors was found to be located in the body or middle one third of the stomach (26.5% versus 21.8%). When comparing the UICC/AJCC stage groupings, the MSKCC patients showed a higher percentage of stage III tumors, while a higher percentage of patients presented to MRI with stage I disease. This tendency also shows in the pT category (depth of invasion): at MRI a higher percentage of patients with pT1/2 category were treated, while a higher percentage of pT3 categories were admitted to MSKCC. Nodal status of patients was comparable, with a mean of 4 positive nodes per patient, respectively. There were, however, striking differences between the 2 institutions in the relationship of total versus subtotal gastrectomies. While at MSKCC, preferably subtotal gastrectomies were performed (79.9%); a FIGURE 1. Nomogram estimating disease-specific survival for R0 resected gastric carcinoma, adapted from Kattan et al. 1 NumPosNodes, number of positive nodes; Num-NegNodes, number of negative nodes; Prob., probability; A/P, antrum or pyloric; B/M, body or middle one third; GEJ, gastroesophageal junction; P/U, proximal or upper one third; int, intestinal; mix, mixed; Dif, diffuse; MM, mucosa; MP, propria muscularis; S1, suspected serosal invasion; S2, definite serosal invasion; S3, adjacent organ involvement; SM, submucosa; SS, subserosa.
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Gastric Cancer Survival Prediction total gastrectomy was the standard procedure at MRI (76%). At MSKCC, tumors located at the GEJ were mostly treated by a proximal subtotal gastrectomy with extension to the distal esophagus (esophageal/proximal) when required by tumor-spread (81.7%), while at MRI a total gastrectomy with extension to the distal esophagus was routinely performed for tumors in this location (97.6%) (esophageal/total). The lymph node dissection was more extended at MRI with a median of 35 compared with 21 nodes removed per patient at MSKCC. In the MSKCC population, age at diagnosis (P Ͻ 0.001), primary site (P Ͻ 0.001), number of positive nodes (P Ͻ 0.01), and depth of invasion (P Ͻ 0.001) were significantly associated with disease-specific survival in the Cox model. Sex was marginally significant (P ϭ 0.06), whereas Lauren histotype (P ϭ 0.26) and size (P ϭ 0.58) were not. 1 Likewise, age at diagnosis (P Ͻ 0.001), primary site (P ϭ 0.04), number of positive nodes (P Ͻ 0.001), and depth of invasion (P Ͻ 0.001) had a significant impact on diseasespecific survival of the MRI patients. Additionally, the number of negative nodes removed (P ϭ 0.01) and the presence of postoperative complications (P Ͻ 0.01) were identified as independent predictors of disease-specific survival. Sex (P ϭ 0.93), Lauren histotype (P ϭ 0.44), and tumor size (P ϭ 0.92) were not significantly associated with disease-specific survival. Additional factors, such as Karnofski performance status (P ϭ 0.19), the presence of lymphangiosis carcinomatosa (P ϭ 0.74), and grading (P ϭ 0.57), had no significant impact on patient survival ( Table 2) .
Predictions from the nomogram were compared with those obtained using the UICC/AJCC stage groupings. Nomogram discrimination was superior to that of UICC/AJCC stage groupings (concordance index 0.770 versus 0.756; P Ͻ 0.008). Hereby the advantage of the combined prognostic factors expressed through the nomogram over the UICC/ AJCC stage groupings, based on TNM, is shown in Figure 2 . The heterogeneity, particularly in the groups II and IIIA, seen in the MSKCC population 1 can also be found in the MRI patients. Figure 3a illustrates the Kaplan-Meier curves for the MRI patients stratified by quadrants of prediction from the MSKCC nomogram. Patients were clustered into 4 groups according to their nomogram-predicted survival (first quartile, Ͻ25%; second quartile, 25% to 50%; third quartile, 50% to 75%; 4th quartile, Ͼ75%). For each of the 4 strata, the Kaplan-Meier curve is within the boundaries of 5-year prediction, as would be desired.
DISCUSSION
Surgical treatment is still the mainstay of curative gastric cancer treatment. For patients who underwent surgery, prognosis is determined by a series of factors, 7, 8 among which depth of invasion, 4,8,9 -13 nodal status, 8 -10,12,14 and metastasis 4, 8, 12 are the most important and lead to the formation of the UICC/AJCC stage formula, which is the most recognized system to predict prognosis. In addition, certain multivariate analyses could identify extent of lymphadenectomy, [11] [12] [13] Borrmann classification, 11, 12 lymph node ratio (ratio between positive and removed nodes), 4, 8, 13 tumor diameter, 8, 12, 13 distant metastases, 4, 8, 12, 13 residual tumor, 4, 8, 13 grading, 13 sex, 11 vessel infiltration, 11 and DNA ploidy 11 as independent prognostic factors. In recent years, other factors, such as lymph node microinvolvement, 15 free peritoneal tumor cells, 16 microsatellite instability, [17] [18] [19] loss of tumor suppressor genes, 20 and a multitude of molecular mark- 16,20 -24 have been reported to be of prognostic relevance in gastric cancer survival. Newly available genomic technologies and approaches, like the analysis of gastric carcinoma expression profiles using the cDNA array 25 or the tissue array method, 20, 26, 27 enable scientists to accumulate genetic information at a rapid pace, so that the number of prognosticators can be expected to steadily increase in the near future. Problems still remain are including the limited number of cases studied, 25 the often missing long-term follow-up and the high costs of the methods.
What clinicians in the field need are prognostic indicators that are easy to assess. In the first case, prognosis is of interest to the patient. Being able to provide the patient with a realistic estimation of his life expectancy makes more effective individual counseling possible. What is more important to the clinician is the fact that knowledge about prognosis is essential whenever multimodal treatment is considered. The expected prognosis has great impact on the kind of treatment a patient will receive. This should consequently help to avoid undertreatment and overtreatment for ethical as well as monetary reasons.
For gastric carcinoma, surgery is the essential step in curative treatment. Recently, adjuvant therapies after gastric carcinoma resection have become a matter of discussion. 28, 29 The trials in question, however, included a wide variety of different tumor stages, so that adjuvant treatment was administered no matter how advanced the tumor was. Future studies in this field should be stratified on the basis of predicted individual risk to later on select those patients who benefit the most from an adjuvant treatment. Figure 3b shows that the UICC/AJCC 30 classification, an established tool for cancer survival prediction based on easy accessible clinical parameters, divides the patient population into groups of different survival and allows a good discrimination between those groups. Subgroup analyses of adjuvant treatment trials indicate a survival benefit of larger magnitude for patients with node-positive disease, especially pronounced in UICC/AJCC stage III. [31] [32] [33] The advantage of the nomogram proposed by Kattan et al 1 is the ability to predict individual survival of a patient and not just of patients within one stage grouping. This advantage is depicted in Figure 2 : especially for patients in stage II and IIIA individual survival prediction by UICC/AJCC stage shows a high degree of inaccuracy. When stratified by UICC/AJCC patients within a stage would be assigned the same prognosis, while nomogram predictions differ a lot within stages II and IIIA. Since nomogram discrimination was significantly superior to that of UICC/AJCC stage groupings, it may be suggested that survival, especially for patients with stage II and IIIA tumors, is influenced by factors that are not included in the UICC/AJCC classification, an issue that should be kept in mind when designing future prospective adjuvant treatment trials.
An important statement that is implicated by the nomogram is the notion that a lower number of examined nonmetastastic nodes results in a poorer outcome, a finding that goes well along with observations reported previously. 15 This finding can be explained by the phenomenon of lymph node microinvolvement or micrometastases, not detected by standard histopathologic assessment. 4 Noteworthy is also the fact that increasing age positively influences prognosis under an age of 60, while over 60 it is associated with a worse prognosis. In other words, young age at diagnosis/surgery is associated with a worse outcome. The association of young age with a worse prognosis remains controversial. While some investigators report adverse clinical and pathologic features in young patients, 34 -36 stagespecific and mean survival has in most cases been found to be similar to an older population. 35, 37, 38 The negative prognostic impact in the nomogram could be explained by a delayed diagnosis because of the relatively uncommon presentation of gastric cancer in the young age and the consequent presentation at advanced stages. 39 -41 FIGURE 3. A, Patient survival stratified by quartiles of nomogram predictions for 60-month disease-free survival (1st quartile, Ͻ25%; 2nd quartile, 25%-50%; 3rd quartile, 50%-75%; 4th quartile, Ͼ75%). Kaplan-Meier curve within the boundaries of nomogram-predicted survival at 60 months. B, Survival of all patients (n ϭ 862) receiving R0 gastric cancer resection at Klinikum rechts der Isar from 1985 to 2003 that were used for nomogram-evaluation stratified by Internation Union Against Cancer stage groupings. Good discrimination between groups at 60 and 108 months.
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Annals of Surgery • Volume 243, Number 1, January 2006 The MRI and MSKCC patients were comparable in distribution of nearly all variables. Differences in the distribution of tumor location, especially tumors located in the proximal one third, might be explained by certain incongruities in defining the esophagogastric junction. In Munich, tumors of the esophagogastric junction are subdivided into adenocarcinoma of the distal esophagus (AEG type I tumors), true carcinoma of the gastric cardia (AEG type II tumors), and subcardial gastric carcinoma infiltrating the esophagogastric junction (AEG type III tumors). 42 As carcinomas of the distal esophagus AEG I were excluded, tumors of the esophagogastric junction comprised of AEG type II and III tumors in the present analysis. The tendency that patients seemed to present in Munich at earlier stages might be explained by the different healthcare systems in Germany and the United States.
When comparing actual survival in the MRI group to the nomogram predictions by tumor location and UICC/ AJCC stage ( Fig. 4) , nomogram predictions seem to match actual survival in nearly all respects. Looking at the standard errors, none of the depicted differences reaches the level of significance.
The nomogram, however, shows a trend to underestimate survival of patients with stage II/IIIA tumors in the MRI population, especially in the predictions for 108-month disease-free survival. This might be attributed to the tendency toward a more radical lymphadenectomy in the Munich population (Table 1 ). An important finding since the extent of lymphadenectomy is the only factor that can be influenced by the surgeon. In the German Gastric Cancer Study, D2 lymph node dissection could be identified as the strongest independent predictor of long-term survival in patients with stage II tumors. 4 Hereby removal of more than 25 lymph nodes was classified as a D2 lymph node dissection, based on anatomic investigations. 43 On analyzing the subgroups, a survival benefit could be detected for patients in pN0 and pN1 categories (pT2N1 and pT3N0), 4 indicating that lymphadenectomy is beneficial not only for patients with lymph node metastases detected by standard histopathologic assessment. This phenomenon can be explained by lymph node microinvolvement or micrometastases only detected by sophisticated staining techniques and multiple sections through each node. 44, 45 Based on this kind of workup, one can assume to detect more positive nodes that otherwise would be diagnosed as nonmetastatic.
The difference observed between predicted and actual survival in this case also suggests that the nomogram may be used to estimate the impact of new adjuvant strategies on survival prior to randomized trials; ie, if a new treatment modality is considered and the observed outcome is better than the predicted, it may be suggested that the new modality is superior to conventional treatment.
The nomogram could also be used to stratify patients before entering adjuvant treatment trials on the basis of their predicted prognosis and thus help to identify the beneficiaries of the therapy in question.
In this context, the differences in the distribution of subtotal versus total gastrectomies in the patient populations from the 2 institutions seem to play a subordinate role as long as a R0 resection is achieved. The impact of a greater resection margin would be more pronounced at the earlier time point, since it should mostly be associated with early local recurrence.
Taken together, the nomogram proposed by Kattan et al was able to predict disease-free survival with a discrimination superior to the UICC/AJCC stage groupings. This is explained by a more individualized approach by consideration of more variables of prognostic relevance, among them also some that did not reach the level of significance in a multivariate model. 1 The reason is the way the nomogram was created: clinicians were asked for factors that they felt theoretically should be predictive, which were then used as nomogram variables. An alternative way of choosing those variables would have been to perform a univariate and multivariate analysis of variables in the patient database and select those with a significant impact on disease-specific survival as predictors along with factors, which appeared 
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Gastric Cancer Survival Prediction relevant in analyses of other groups. However, such an approach will tend to yield a prediction model that is inferior to the full model containing all predictors thought to be prognostic. 46 In a multivariate analysis of prognostic factors of the data collected by the German Gastric Cancer Study Group, as well as in the present analysis (Table 2) , the presence of postsurgical complications was identified as an important prognostic factor in patients with R0 resection 4 and would therefore qualify for inclusion into the nomogram. Apart from most of the factors already included by Kattan et al, 1 the Borrmann classification has been found to be of prognostic value in certain analyses; 11, 12 which is however not routinely assessed in most hospitals. The presence of angioinvasion 11 and lymphangiosis carcinomatosa 47, 48 has also been shown to influence postoperative survival after gastric cancer resection. Phase II and III data seem to indicate that neoadjuvant chemotherapy positively influences postoperative diseasespecific survival; 49 therefore, this factor should also find inclusion in a future nomogram. To strengthen the predictive ability of the model, additional variables taken from a survey among clinicians should be included.
CONCLUSION
Validation of the Kattan nomogram, allowing for a individualized prediction of disease-specific survival after R0 gastric cancer resection, on the patient data collected at a European high-volume center showed that its use is not only confined to the institution where it was created, but it can be adopted by other institutions with similar surgical strategies. Routine clinical use, however, should be preceded by validation on the patient database of the individual surgical department.
